Market closed

Esperion Therapeutics/$ESPR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Esperion Therapeutics

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Ticker

$ESPR
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
Ann Arbor, United States

Employees

-
Website
www.esperion.com

ESPR Metrics

BasicAdvanced
$449M
-
-$0.52
0.95
-

$449M

0.95

$3.40

$1.58

7.2M

1.854

1.281

-71.911

-72.651

0.28%

3.84%

22.24%

1.284

-1.2

-1.2

-14.55

187.12%

-76.64%

59.59%

-64.53%

What the Analysts think about ESPR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Esperion Therapeutics stock.

ESPR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ESPR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ESPR News

AllArticlesVideos
Esperion Announces $210 Million Convertible Debt Financing

Esperion Announces $210 Million Convertible Debt Financing

GlobeNewsWire·1 month ago
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

GlobeNewsWire·1 month ago
Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ESPR

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Esperion Therapeutics stock?

Esperion Therapeutics (ESPR) has a market cap of $449M as of January 15, 2025.

What is the P/E ratio for Esperion Therapeutics stock?

The price to earnings (P/E) ratio for Esperion Therapeutics (ESPR) stock is 0 as of January 15, 2025.

Does Esperion Therapeutics stock pay dividends?

No, Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Esperion Therapeutics dividend payment date?

Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders.

What is the beta indicator for Esperion Therapeutics?

Esperion Therapeutics (ESPR) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.